- Home
- IDAI vs ADXN Comparison
IDAI vs ADXN Comparison
Compare IDAI & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDAI
- ADXN
- Stock Information
- Founded
- IDAI 2016
- ADXN 2002
- Country
- IDAI United States
- ADXN Switzerland
- Employees
- IDAI N/A
- ADXN N/A
- Industry
- IDAI Computer Software: Prepackaged Software
- ADXN Biotechnology: Pharmaceutical Preparations
- Sector
- IDAI Technology
- ADXN Health Care
- Exchange
- IDAI Nasdaq
- ADXN Nasdaq
- Market Cap
- IDAI 7.7M
- ADXN 8.0M
- IPO Year
- IDAI N/A
- ADXN N/A
- Fundamental
- Price
- IDAI $3.14
- ADXN $10.01
- Analyst Decision
- IDAI
- ADXN Strong Buy
- Analyst Count
- IDAI 0
- ADXN 1
- Target Price
- IDAI N/A
- ADXN $30.00
- AVG Volume (30 Days)
- IDAI 31.0K
- ADXN 58.4K
- Earning Date
- IDAI 11-14-2025
- ADXN 09-01-2025
- Dividend Yield
- IDAI N/A
- ADXN N/A
- EPS Growth
- IDAI N/A
- ADXN N/A
- EPS
- IDAI N/A
- ADXN 0.10
- Revenue
- IDAI $3,366,415.00
- ADXN $278,508.00
- Revenue This Year
- IDAI $25.13
- ADXN $86.57
- Revenue Next Year
- IDAI $48.09
- ADXN N/A
- P/E Ratio
- IDAI N/A
- ADXN $0.85
- Revenue Growth
- IDAI N/A
- ADXN N/A
- 52 Week Low
- IDAI $1.43
- ADXN $6.51
- 52 Week High
- IDAI $18.75
- ADXN $12.05
- Technical
- Relative Strength Index (RSI)
- IDAI 57.02
- ADXN 62.18
- Support Level
- IDAI $2.92
- ADXN $7.70
- Resistance Level
- IDAI $3.34
- ADXN $12.05
- Average True Range (ATR)
- IDAI 0.22
- ADXN 0.30
- MACD
- IDAI 0.02
- ADXN 0.22
- Stochastic Oscillator
- IDAI 68.53
- ADXN 43.69
About IDAI T Stamp Inc.
T Stamp Inc develops and markets identity authentication software solutions for enterprise partners and peer-to-peer markets. The company is engaged in developing proprietary artificial intelligence-powered solutions; researching and leveraging biometric science, cryptography, and data mining to deliver insightful identity & trust predictions while identifying and defending against fraudulent identity attacks, protecting sensitive user information, and extending the reach of digital services through accessibility. The artificial intelligence-powered solutions segment generates revenue principally from software licenses, professional services, and recurring Software-as-a-Service ("SaaS") revenue.
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.